JP4381685B2 - 2型インスリン抵抗性真性糖尿病患者の治療のためのビオチンと組合せてのアセチルl−カルニチンの使用 - Google Patents
2型インスリン抵抗性真性糖尿病患者の治療のためのビオチンと組合せてのアセチルl−カルニチンの使用 Download PDFInfo
- Publication number
- JP4381685B2 JP4381685B2 JP2002592920A JP2002592920A JP4381685B2 JP 4381685 B2 JP4381685 B2 JP 4381685B2 JP 2002592920 A JP2002592920 A JP 2002592920A JP 2002592920 A JP2002592920 A JP 2002592920A JP 4381685 B2 JP4381685 B2 JP 4381685B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- carnitine
- acetyl
- biotin
- per day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
1−インスリン依存性真性糖尿病(1型糖尿病とも称される);この型の糖尿病を患う患者は、ケトアシドーシスおよび死を免れるために文字通り外因性インスリンに依存する。内因性インスリン分泌に関する限りは、1型真性糖尿病を患う患者はインスリン減少症(insulinopenia)を示す。
2−非インスリン依存性真性糖尿病(2型糖尿病とも称される);この型の糖尿病患者は生存のためにインスリンを必要としない;患者は糖尿病の症状を制御するためにインスリンを使用するか否かを決定できる。内因性インスリン分泌に関して、2型糖尿病患者はさらに2つのグループに分類される。第1のグループでは、インスリンレベルは正常または正常よりも低い;第2のグループでは、インスリン値は正常より高く、患者はインスリン抵抗性を示す。
Claims (5)
- ビオチン、およびアセチルL−カルニチンまたはその医薬上許容される塩を組み合わせて含有する、2型インスリン抵抗性糖尿病の治療薬。
- 塩が、塩化物、臭化物、オロチン酸塩、酸アスパラギン酸塩、酸クエン酸塩、クエン酸マグネシウム塩、酸リン酸塩、フマル酸塩および酸フマル酸塩、フマル酸マグネシウム塩、乳酸塩、マレイン酸塩および酸マレイン酸塩、ムケート、酸シュウ酸塩、パモ酸塩、酸パモ酸塩、酸硫酸塩、グルコースリン酸塩、酒石酸塩、酸酒石酸塩、酒石酸マグネシウム塩、2−アミンエタンスルホン酸塩、マグネシウム2−アミンエタンスルホン酸塩、酒石酸コリン塩およびトリクロロ酢酸塩からなる群から選択される、請求項1に記載の治療薬。
- アセチルL−カルニチンの投与量が1日当たり0.1から2gであり、ビオチンの投与量が1日当たり1から8mgであるよう調製された、請求項1に記載の治療薬。
- アセチルL−カルニチンの投与量が1日当たり0.2から1gであり、ビオチンの投与量が1日当たり3から5mgであるよう調製された、請求項3に記載の治療薬。
- アセチルL−カルニチンの投与量が1日当たり0.3gであり、ビオチンの投与量が1日当たり4mgであるよう調製された、請求項4に記載の治療薬。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT2001RM000294A ITRM20010294A1 (it) | 2001-05-29 | 2001-05-29 | Uso della acetil l-carnetina in associazione con la biotina per il trattamento di pazienti affetti da diabete mellito di tipo ii insulino re |
PCT/IT2002/000338 WO2002096410A1 (en) | 2001-05-29 | 2002-05-24 | Use of the acetyl l-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2004532866A JP2004532866A (ja) | 2004-10-28 |
JP2004532866A5 JP2004532866A5 (ja) | 2006-01-05 |
JP4381685B2 true JP4381685B2 (ja) | 2009-12-09 |
Family
ID=11455558
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002592920A Expired - Fee Related JP4381685B2 (ja) | 2001-05-29 | 2002-05-24 | 2型インスリン抵抗性真性糖尿病患者の治療のためのビオチンと組合せてのアセチルl−カルニチンの使用 |
Country Status (18)
Country | Link |
---|---|
US (2) | US20040142879A1 (ja) |
EP (1) | EP1399142B1 (ja) |
JP (1) | JP4381685B2 (ja) |
KR (1) | KR20040010666A (ja) |
AT (1) | ATE333274T1 (ja) |
CA (1) | CA2448244C (ja) |
CY (1) | CY1105403T1 (ja) |
CZ (1) | CZ297743B6 (ja) |
DE (1) | DE60213237T2 (ja) |
DK (1) | DK1399142T3 (ja) |
ES (1) | ES2268053T3 (ja) |
HU (1) | HUP0400060A2 (ja) |
IT (1) | ITRM20010294A1 (ja) |
MX (1) | MXPA03010921A (ja) |
PL (1) | PL207522B1 (ja) |
PT (1) | PT1399142E (ja) |
SK (1) | SK287832B6 (ja) |
WO (1) | WO2002096410A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE339445T1 (de) * | 2000-12-15 | 2006-10-15 | Sigma Tau Ind Farmaceuti | Verwendung von l-carnitin als stabilitsator für proteine |
ITRM20040327A1 (it) * | 2004-07-01 | 2004-10-01 | Sigma Tau Ind Farmaceuti | Uso della acetil l-carnitina per la preparazione di un medicamento per il trattamento del dolore neuropatico in pazienti diabetici. |
US8569366B2 (en) * | 2005-04-26 | 2013-10-29 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Acetyl L-carnitine for prevention of painful peripheral neuropathy in patients with type 2 diabetes |
EP1832295A1 (en) * | 2006-03-10 | 2007-09-12 | Tecnogen S.P.A. | Use of PTX3 for the treatment of viral diseases |
SG193655A1 (en) * | 2007-03-21 | 2013-10-30 | Sigma Tau Ind Farmaceuti | Composition useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance |
GB201304112D0 (en) * | 2013-03-07 | 2013-04-24 | Univ Nottingham | Modulation of energy expenditure |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1196564B (it) * | 1986-08-04 | 1988-11-16 | Sigma Tau Ind Farmaceuti | Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche |
IT1263004B (it) * | 1992-10-08 | 1996-07-23 | Sigma Tau Ind Farmaceuti | Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti. |
US6020139A (en) * | 1995-04-25 | 2000-02-01 | Oridigm Corporation | S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy |
US5789401A (en) * | 1997-08-08 | 1998-08-04 | Nutrition 21 | High-dose chromium/biotin treatment of type II diabetes |
-
2001
- 2001-05-29 IT IT2001RM000294A patent/ITRM20010294A1/it unknown
-
2002
- 2002-05-24 ES ES02741155T patent/ES2268053T3/es not_active Expired - Lifetime
- 2002-05-24 DK DK02741155T patent/DK1399142T3/da active
- 2002-05-24 CA CA2448244A patent/CA2448244C/en not_active Expired - Fee Related
- 2002-05-24 HU HU0400060A patent/HUP0400060A2/hu unknown
- 2002-05-24 SK SK1585-2003A patent/SK287832B6/sk not_active IP Right Cessation
- 2002-05-24 AT AT02741155T patent/ATE333274T1/de active
- 2002-05-24 EP EP02741155A patent/EP1399142B1/en not_active Expired - Lifetime
- 2002-05-24 CZ CZ20033221A patent/CZ297743B6/cs not_active IP Right Cessation
- 2002-05-24 DE DE60213237T patent/DE60213237T2/de not_active Expired - Lifetime
- 2002-05-24 KR KR10-2003-7015575A patent/KR20040010666A/ko not_active Application Discontinuation
- 2002-05-24 US US10/478,372 patent/US20040142879A1/en not_active Abandoned
- 2002-05-24 MX MXPA03010921A patent/MXPA03010921A/es active IP Right Grant
- 2002-05-24 WO PCT/IT2002/000338 patent/WO2002096410A1/en active IP Right Grant
- 2002-05-24 JP JP2002592920A patent/JP4381685B2/ja not_active Expired - Fee Related
- 2002-05-24 PT PT02741155T patent/PT1399142E/pt unknown
- 2002-05-24 PL PL367630A patent/PL207522B1/pl not_active IP Right Cessation
-
2006
- 2006-09-25 CY CY20061101375T patent/CY1105403T1/el unknown
-
2008
- 2008-07-02 US US12/216,279 patent/US8053472B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CY1105403T1 (el) | 2010-04-28 |
PL207522B1 (pl) | 2010-12-31 |
CZ20033221A3 (cs) | 2004-06-16 |
EP1399142B1 (en) | 2006-07-19 |
DE60213237T2 (de) | 2007-08-02 |
PT1399142E (pt) | 2006-10-31 |
SK15852003A3 (sk) | 2004-04-06 |
ATE333274T1 (de) | 2006-08-15 |
DE60213237D1 (de) | 2006-08-31 |
EP1399142A1 (en) | 2004-03-24 |
CZ297743B6 (cs) | 2007-03-21 |
HUP0400060A2 (hu) | 2004-04-28 |
CA2448244C (en) | 2010-11-02 |
ES2268053T3 (es) | 2007-03-16 |
DK1399142T3 (da) | 2006-10-30 |
ITRM20010294A0 (it) | 2001-05-29 |
JP2004532866A (ja) | 2004-10-28 |
ITRM20010294A1 (it) | 2002-11-29 |
US20040142879A1 (en) | 2004-07-22 |
CA2448244A1 (en) | 2002-12-05 |
SK287832B6 (sk) | 2011-11-04 |
KR20040010666A (ko) | 2004-01-31 |
PL367630A1 (en) | 2005-03-07 |
US8053472B2 (en) | 2011-11-08 |
US20080269307A1 (en) | 2008-10-30 |
WO2002096410A1 (en) | 2002-12-05 |
MXPA03010921A (es) | 2004-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5157022A (en) | Method for reducing blood cholesterol using arginine | |
Rigante et al. | The pharmacologic basis of treatment with colchicine in children with familial Mediterranean fever | |
JP3699124B2 (ja) | タイプii糖尿病のピコリン酸クロム高用量治療 | |
SK283853B6 (sk) | Terapeutická/výživová kompozícia pre diabetikov | |
US8053472B2 (en) | Use of the acetyl L-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus | |
JP4804353B2 (ja) | 糖尿病の治療及び予防のためのフタリド誘導体の使用 | |
EP1021087A1 (en) | Serotonin containing formulation for oral administration and method of use | |
KR20070086007A (ko) | 당뇨병의 치료를 위한 의약 조성물 | |
EP4331583A1 (en) | Blood carnitine-increasing agent | |
JPH06227983A (ja) | エイズ治療のためのl−カルニチン類の使用 | |
JP7344422B2 (ja) | 糖尿病予防・治療用の医薬品組成物及びその用途 | |
CN116490181A (zh) | 在人中施用β-羟基丁酸和相关化合物用于治疗和/或预防呼吸道疾病 | |
WO2020222302A1 (ja) | 新規医薬組成物 | |
KR20050121196A (ko) | 심혈관 질환의 치료를 위한 l―카르니틴의 용도 | |
JPH05194207A (ja) | 特発性精子過少症の処置のためのl−カルニチンおよびアシル−l−カルニチンの使用 | |
KR101296479B1 (ko) | 심혈관 질환 치료를 위한 l-카르니틴 및 글루코오스의용도 | |
WO2023156275A1 (en) | Pharmaceutical composition and medicament comprising l-tryptophan, l-5-hydroxytryptophan and a peripheral degradation inhibitor | |
CN112512526A (zh) | 化合物a与化合物b联合在制备治疗痛风或高尿酸血症的药物中的用途 | |
EP2124925A1 (en) | Composition useful for the treatment of type 2 diabetes | |
JP2006193511A (ja) | 糖尿病の治療のための医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050523 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050523 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090106 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090908 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090916 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121002 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131002 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |